 The purpose of this study is to evaluate the safety and efficacy of autologous Platelet Rich Plasma PRP and Platelet Poor Plasma PPP eye drops four times a day in the treatment of ocular graft versus host disease O-GVHD. In addition to their current medication except autologous serum drops, patients will receive PRP and PPP drops. 